Alzheimer’s Disease Treatment in India for International Patients

Alzheimer’s disease progressively affects memory, reasoning, communication and everyday independence. Although there is no cure, diagnosis and an individualised care plan can help manage symptoms and, for some eligible people in the early stages, slow cognitive decline. India offers neurological assessment, diagnostic testing, medication and supportive care. MedTripz helps international families coordinate medical opinions, treatment options, cost estimates and travel arrangements.

What Is Alzheimer’s Disease?

Alzheimer’s is associated with progressive damage to nerve cells and changes involving amyloid plaques and tau protein. Early symptoms may include difficulty remembering recent conversations or appointments. Later, language, judgement, planning, orientation, mood and behaviour may also be affected. The rate of progression varies. Alzheimer’s is one cause of dementia, not a synonym for every form of dementia, and other conditions can cause similar symptoms.

When Should a Person Be Evaluated?

Seek an assessment when persistent or worsening changes affect daily independence. Signs may include:

• Repeatedly asking the same questions or forgetting recent events.

• Difficulty managing money, medicines, familiar tasks or appointments.

• Losing the way in familiar surroundings.

• Trouble finding words, following conversations or making decisions.

• Noticeable changes in judgement, mood, personality or social behaviour.

Sudden confusion or an abrupt change in mental state is not typical of gradual Alzheimer’s progression and needs urgent medical assessment. It may be associated with infection, medication effects, stroke or another acute condition.

How Is Alzheimer’s Disease Diagnosed?

No single test confirms the diagnosis in isolation. Assessment combines patient and caregiver history, cognitive testing, examination and selected investigations.

Medical History and Cognitive Assessment

The clinician reviews symptom onset, progression and effect on daily life. A caregiver can describe changes the patient may not recall. Standardised tests assess memory, attention, language, orientation and problem-solving; detailed neuropsychological testing may be used when needed.

Physical and Neurological Examination

The examination may assess reflexes, strength, balance, coordination, hearing and vision, alongside medical conditions and medicines that can affect cognition.

Blood Tests

Blood tests may check for contributors such as thyroid dysfunction, vitamin B12 deficiency or metabolic abnormalities. The panel depends on the patient's history.

Brain Imaging and Biomarker Tests

MRI can assess brain structure and help identify other causes, such as stroke or a tumour; CT may be used if MRI is unsuitable. Selected patients may need PET imaging or cerebrospinal fluid tests for amyloid and tau. Blood biomarkers are an evolving option and must be interpreted with clinical findings, not used as a stand-alone diagnosis.

Alzheimer’s Disease Treatment Options in India

Treatment depends on disease stage, symptoms, medical history, safety and patient goals. It aims to maintain function, manage symptoms and support caregivers.

Medicines for Cognitive Symptoms

Donepezil, rivastigmine and galantamine may be prescribed for selected patients, commonly in mild to moderate disease, to support nerve-cell communication and provide modest symptom relief. Side effects can include nausea, diarrhoea, appetite loss and sleep problems. Memantine may be used in moderate to severe disease, alone or with another medicine; dizziness, headache and constipation are possible. A specialist selects and monitors treatment.

Disease-Modifying Treatment for Eligible Early-Stage Patients

Anti-amyloid medicines may be considered for selected people with early symptomatic disease—mild cognitive impairment or mild dementia due to Alzheimer’s—with confirmed amyloid pathology. They are not suitable for everyone and do not cure the disease.

Donanemab received marketing authorisation in India in November 2025 and was launched in May 2026. It is a prescription intravenous treatment administered on a scheduled basis. Eligibility requires specialist assessment and confirmation of the relevant disease stage and amyloid pathology.

These medicines can cause amyloid-related imaging abnormalities (ARIA), including brain swelling or small areas of bleeding, which may be serious. Treatment therefore requires baseline and follow-up MRI monitoring, assessment of risk factors and careful review of other medicines, including blood thinners. The specialist explains potential benefits, risks, monitoring commitments and costs before treatment begins. Availability and prescribing criteria should be reconfirmed at the time of consultation.

Supportive and Non-Drug Care

Supportive care may include cognitive stimulation, occupational or communication therapy, suitable physical activity, nutrition guidance and help with sleep or behavioural symptoms. It does not reverse the disease but may support comfort and daily function.

Daily Care and Support for Families

A calm, predictable routine can reduce confusion. Calendars, reminders, consistent storage places, simplified tasks, good lighting and clear walkways may improve safety. Encourage balanced meals, fluids, appropriate activity and meaningful social contact. Do not use supplements or herbal products as treatment without medical advice because evidence is limited and interactions are possible. Caregivers should share responsibilities, take breaks and seek support when needed.

Alzheimer’s Disease Treatment Cost in India

The Alzheimer’s Disease Treatment Cost in India depends on the diagnostic work-up, stage of disease, medicines selected, need for biomarker confirmation, frequency of specialist reviews and duration of follow-up. Costs can differ substantially between symptom-management care and newer disease-modifying treatment, which may require repeated infusions and MRI monitoring.

The MedTripz webpage currently displays an indicative range of USD 10,000–25,000, with an average of USD 15,000. This is a website-listed estimate, not a universal or guaranteed package price. The page does not specify which investigations, medicines, infusion sessions or follow-up services are included. Families should request a current, itemised estimate based on the proposed care plan before making travel arrangements.

A written estimate should clarify consultation fees, cognitive and laboratory testing, MRI or PET scans, biomarker investigations, medicine costs, infusion and monitoring charges, follow-up appointments and any accommodation or travel expenses. Long-term medicine and care costs may continue after the patient returns home.

Why International Patients Consider India

India offers neurological specialists, diagnostic facilities and access to established and newer treatment approaches. Families can compare care plans and costs, while considering medicine access, monitoring and continuity of follow-up—not only the initial price.

For patients and families from the Middle East, Africa and CIS, planning should include continuity of care after returning home. Before travelling, families should confirm whether the required medicine and MRI schedule can be maintained, who will review results and how urgent concerns will be handled.